-
Aurora Cannabis Launches Innovative THC Oil Products In Australia To Meet Diverse Patient Needs
Wednesday, October 16, 2024 - 10:54am | 591Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) together with MedReleaf Australia, announced on Wednesday an enhanced product range of premium medical cannabis oil in Australia. The Canadian medical cannabis giant said the new cannabis oils include a variety of cannabinoid ratios to suit diverse...
-
EXCLUSIVE: New Alzheimer's Treatment? Promising Cannabinoid Compound Shows Hope, InMed CEO Says
Friday, June 21, 2024 - 3:41pm | 564InMed Pharmaceuticals is making strides in Alzheimer’s research with its development of a cannabinoid-based compound that aims to protect and rejuvenate brain neurons. During Benzinga’s virtual event on Thursday, InMed president and CEO Eric A. Adams shared detailed insights into the...
-
Weed Potency Has Increased Dramatically Over Last Several Decades, How High Can THC Limits Go?
Friday, May 17, 2024 - 4:14pm | 832In the last half-century, cannabis has transformed significantly, with THC levels – the primary psychoactive component in the plant – increasing exponentially. This surge reflects advances in cultivation techniques and shifting market demand for products with more powerful effects,...
-
This Company Leads The Way In Cannabinoid Treatment Innovation With New Patent
Tuesday, October 3, 2023 - 11:09am | 358SciSparc Ltd. (NASDAQ: SPRC) announced on Tuesday that the European Patent Office has granted it a new patent. The European Application No. 16786064.2 - titled Combinations of Cannabinoids and N-Acylethanolamines - aligns with the company's objective to increase the safety of cannabinoid...
-
ICYMI: THCV - The Rare Cannabinoid That'll Conquer The Industry
Thursday, July 7, 2022 - 10:15am | 1037This article was originally published in November 2020. By Maxim Mikheev, CEO and Founder of BIOMEDICAN Now that one-third of Americans live in a state where recreational cannabis is legal, there’s a booming demand for cannabinoids—the compounds found in the cannabis plant. The most...
-
Incannex's Cannabinoid Combo Product Reduces AHI In Sleep Apnea Patients
Thursday, March 10, 2022 - 12:43pm | 316Incannex Healthcare Limited (NASDAQ: IXHL) has completed a preliminary analysis of data from its Phase 2 trial of a cannabinoid combination product, IHL-42X, for obstructive sleep apnoea (OSA). The clinical trial assessed three doses of IHL-42X at reducing the apnoea hypopnoea index...
-
Vyripharm Enterprises & CSU Pueblo To Provide Consistency Of Cannabinoid Analysis, Poised To Launch New Testing Lab
Thursday, March 10, 2022 - 9:09am | 385Vyripharm Enterprises, Inc. and CSU Pueblo have partnered to support the creation of a comprehensive testing and certification laboratory that will provide the first consistent scientific analysis within cannabinoid research. What Happened? Vyripharm Enterprises, a Texas biopharmaceutical/...
-
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?
Wednesday, December 8, 2021 - 10:19am | 308Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data showed that after a single day of dosing, the processed CBD reduced arterial stiffness, potentially broadening its...
-
Cannabinoids Company InMed Pharma Posts Smaller Net Loss For FY21
Friday, September 24, 2021 - 9:21am | 384InMed Pharmaceuticals Inc (NASDAQ: INM) reported an FY21 EPS loss of $(1.52) narrower than $(1.71) posted a year ago. On June 30, the company's cash, cash equivalents, and short-term investments were $7.4 million. R&D and patents expenses were $5.3 million compared to $5.8...
-
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
Tuesday, September 7, 2021 - 9:09am | 320Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension. Related Content: DehydraTECH Delivered Colchicine Can Potentially Treat...
-
Cardiol To Test Oral Cannabidiol Formulation In Acute Myocarditis Patients
Tuesday, August 24, 2021 - 8:24am | 245The FDA has signed off Cardiol Therapeutics Inc's (NASDAQ: CRDL) Investigational New Drug (IND) application for CardiolRx. Cardiol will commence a Phase 2, multi-center, double-blind, randomized, placebo-controlled trial to assess the safety and tolerability of CardiolRx in...
-
China Bans All Synthetic Cannabinoids
Tuesday, May 11, 2021 - 5:31pm | 317This article by Franca Quarneti was originally published on El Planteo, and appears here with permission. The Chinese government has announced that all synthetic cannabinoids will be included in the list of banned drugs. What are synthetic cannabinoids? Synthetic cannabinoids are manufactured...
-
USDA-Certified Organic CBD Isolate: This Company Has Pioneered A Process To Produce It
Wednesday, April 7, 2021 - 2:36pm | 517Tennessee Harvester Enterprises (THE) has pioneered a proprietary process that has yielded the world's first and only USDA-certified Organic Cannabidiol (CBD) isolate. Once thought impossible, due to the prevalent use of hydrocarbons during traditional CBD isolate manufacturing, THE’...
-
BevCanna Closes Naturo Group Acquisition, Announces Debt Settlement And Grant
Monday, February 8, 2021 - 11:52am | 372BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) is taking over a Canadian producer of beverages and consumer products. The Vancouver manufacturer of cannabinoid-infused beverages has entered into an amended and restated agreement to acquire Naturo Group Inc. The move is a step closer to...
-
Is CBD Psychoactive?
Saturday, January 23, 2021 - 12:32pm | 947This article by Daily Hive was originally published on Weedmaps, and appears here with permission. Every day, in every way, cannabis legalization in Canada is getting closer. But despite all the hype, noise, and publicity, there seems to be recurring cannabis myths flying around that...